Pituitary adenoma medical therapy

Pituitary adenoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pituitary adenoma from other Diseases
Epidemiology and Demographics
Risk Factors
Natural history, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pituitary adenoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pituitary adenoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pituitary adenoma medical therapy
CDC on Pituitary adenoma medical therapy
Pituitary adenoma medical therapy in the news
Blogs on Pituitary adenoma medical therapy
Directions to Hospitals Treating Pituitary adenoma
Risk calculators and risk factors for Pituitary adenoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pharmacologic medical therapy is recommended among patients with prolactinoma, thyrotophic adenomas and gonadorophic adenomas.

Medical Therapy

Treatment options depend on the type of tumor and on its size:

• Prolactinomas are most often treated with bromocriptine or more recently, cabergoline which, unlike bromocriptine, decreases tumor size as well as alleviates symptoms, both dopamine agonists, and followed by serial imaging to detect any increase in size. Treatment where the tumor is large can be with radiation therapy or surgery, and patients generally respond well. Efforts have been made to use a progesterone antagonist for the treatment of prolactinomas, but so far have not proved successful.
• Thyrotrophic adenomas respond to octreotide, a long-acting somatostatin analog, in many but not all cases according to a review of the medical literature. Unlike prolactinomas, thyrotrophic adenomas characteristically respond poorly to dopamine agonist treatment.
• Pituitary adenoma is considered an absolute contraindication to the use of clomifene.